Showing results (331-340 of 389) with videos related to
Sort By:
Pageof 39
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2013
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906LYoshihito Kogure, Masahiko Ando, Hideo Saka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trialShuichi Hironaka, Shinya Ueda, Hirofumi Yasui, et al.Translational Lung Cancer Research|July 23, 2021
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancerHiroyuki Inoue, Hirono Tsutsumi, Kentaro Tanaka, et al.Journal for Immunotherapy of Cancer|February 2, 2022
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, et al.Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancerTakeshi Yoshida, Guolin Zhang, Matthew A Smith, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2020
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Luis Paz-Ares, David Vicente, Ali Tafreshi, et al.The Lancet. Oncology|December 22, 2009
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialTetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, et al.The Oncologist|April 17, 2020
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.Pageof 39